139 related articles for article (PubMed ID: 16606347)
1. A fluorescence assay for rapid detection of ligand binding affinity to HIV-1 gp41.
Gochin M; Savage R; Hinckley S; Cai L
Biol Chem; 2006 Apr; 387(4):477-83. PubMed ID: 16606347
[TBL] [Abstract][Full Text] [Related]
2. A novel fluorescence intensity screening assay identifies new low-molecular-weight inhibitors of the gp41 coiled-coil domain of human immunodeficiency virus type 1.
Cai L; Gochin M
Antimicrob Agents Chemother; 2007 Jul; 51(7):2388-95. PubMed ID: 17452484
[TBL] [Abstract][Full Text] [Related]
3. Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41.
Bewley CA; Louis JM; Ghirlando R; Clore GM
J Biol Chem; 2002 Apr; 277(16):14238-45. PubMed ID: 11859089
[TBL] [Abstract][Full Text] [Related]
4. Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides.
Shu W; Liu J; Ji H; Radigen L; Jiang S; Lu M
Biochemistry; 2000 Feb; 39(7):1634-42. PubMed ID: 10677212
[TBL] [Abstract][Full Text] [Related]
5. Thermodynamics of peptide inhibitor binding to HIV-1 gp41.
Cole JL; Garsky VM
Biochemistry; 2001 May; 40(19):5633-41. PubMed ID: 11341828
[TBL] [Abstract][Full Text] [Related]
6. The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors.
Zhu Y; Ding X; Yu D; Chong H; He Y
J Virol; 2019 Dec; 94(1):. PubMed ID: 31619552
[TBL] [Abstract][Full Text] [Related]
7. Design and properties of N(CCG)-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity.
Louis JM; Bewley CA; Clore GM
J Biol Chem; 2001 Aug; 276(31):29485-9. PubMed ID: 11418583
[TBL] [Abstract][Full Text] [Related]
8. Hydrophobic mutations in buried polar residues enhance HIV-1 gp41 N-terminal heptad repeat-C-terminal heptad repeat interactions and C-peptides' anti-HIV activity.
Zheng B; Wang K; Lu L; Yu F; Cheng M; Jiang S; Liu K; Cai L
AIDS; 2014 Jun; 28(9):1251-60. PubMed ID: 24625369
[TBL] [Abstract][Full Text] [Related]
9. The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation.
Dwyer JJ; Hasan A; Wilson KL; White JM; Matthews TJ; Delmedico MK
Biochemistry; 2003 May; 42(17):4945-53. PubMed ID: 12718536
[TBL] [Abstract][Full Text] [Related]
10. Development of a FRET assay for monitoring of HIV gp41 core disruption.
Xu Y; Hixon MS; Dawson PE; Janda KD
J Org Chem; 2007 Aug; 72(18):6700-7. PubMed ID: 17685571
[TBL] [Abstract][Full Text] [Related]
11. The structure of an HIV-1 specific cell entry inhibitor in complex with the HIV-1 gp41 trimeric core.
Zhou G; Ferrer M; Chopra R; Kapoor TM; Strassmaier T; Weissenhorn W; Skehel JJ; Oprian D; Schreiber SL; Harrison SC; Wiley DC
Bioorg Med Chem; 2000 Sep; 8(9):2219-27. PubMed ID: 11026535
[TBL] [Abstract][Full Text] [Related]
12. Conserved residue Lys574 in the cavity of HIV-1 Gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry.
He Y; Liu S; Jing W; Lu H; Cai D; Chin DJ; Debnath AK; Kirchhoff F; Jiang S
J Biol Chem; 2007 Aug; 282(35):25631-9. PubMed ID: 17616522
[TBL] [Abstract][Full Text] [Related]
13. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements.
Ferrer M; Kapoor TM; Strassmaier T; Weissenhorn W; Skehel JJ; Oprian D; Schreiber SL; Wiley DC; Harrison SC
Nat Struct Biol; 1999 Oct; 6(10):953-60. PubMed ID: 10504731
[TBL] [Abstract][Full Text] [Related]
14. Addition of artificial salt bridge by Ile646Lys mutation in gp41 coiled-coil domain regulates 6-helical bundle formation.
Zhao L; Hu ZW; Tong P; Chen YX; Zhao YF; Li YM
Bioorg Med Chem Lett; 2013 May; 23(9):2727-32. PubMed ID: 23522564
[TBL] [Abstract][Full Text] [Related]
15. Peptide and non-peptide HIV fusion inhibitors.
Jiang S; Zhao Q; Debnath AK
Curr Pharm Des; 2002; 8(8):563-80. PubMed ID: 11945159
[TBL] [Abstract][Full Text] [Related]
16. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target.
Chan DC; Chutkowski CT; Kim PS
Proc Natl Acad Sci U S A; 1998 Dec; 95(26):15613-7. PubMed ID: 9861018
[TBL] [Abstract][Full Text] [Related]
17. The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120.
Moseri A; Biron Z; Arshava B; Scherf T; Naider F; Anglister J
FEBS J; 2015 Dec; 282(24):4643-57. PubMed ID: 26432362
[TBL] [Abstract][Full Text] [Related]
18. Conserved residues in the coiled-coil pocket of human immunodeficiency virus type 1 gp41 are essential for viral replication and interhelical interaction.
Mo H; Konstantinidis AK; Stewart KD; Dekhtyar T; Ng T; Swift K; Matayoshi ED; Kati W; Kohlbrenner W; Molla A
Virology; 2004 Nov; 329(2):319-27. PubMed ID: 15518811
[TBL] [Abstract][Full Text] [Related]
19. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
[TBL] [Abstract][Full Text] [Related]
20. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.
Eckert DM; Kim PS
Proc Natl Acad Sci U S A; 2001 Sep; 98(20):11187-92. PubMed ID: 11572974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]